Showing 1291-1300 of 1395 results for "".
- SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Rochehttps://modernod.com/news/semathera-enters-into-a-research-collaboration-and-exclusive-license-agreement-with-roche/2478997/SemaThera announced the signing of a multi-year research collaboration and licensing agreement with Roche to advance SemaThera’s new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases. Terms of the deal were not disclosed. “We are very
- NovaSight Announces First Pivotal Study for Lazy-Eye Digital Treatment Against Gold Standard Patchinghttps://modernod.com/news/novasight-announces-first-pivotal-study-for-lazy-eye-digital-treatment-against-gold-standard-patching/2478980/Israeli startup NovaSight has announced that it is running a large, pivotal multicenter randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for amblyopia (lazy eye). This is the first pivotal study of its kind in children against the gold standard
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- More Data Point to Pfizer, BioNTech Vaccine Cutting COVID-19 Transmission Rateshttps://modernod.com/news/more-data-point-to-pfizer-biontech-vaccine-cutting-covid-19-transmission-rates/2478965/Mounting real-world evidence from Israel suggests that Pfizer and BioNTech’s vaccine BNT162b2 can “dramatically” cut incidence rates of COVID-19 disease in fully vaccinated individuals, according to a joint statement issued Thursday by the companies and the Israeli Ministry of H
- Samsara Vision and Medevise Consulting Announce European Partnershiphttps://modernod.com/news/samsara-vision-and-medevise-consulting-announce-european-partnership/2478956/Samsara Vision announced it will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement,
- UK, Four Other Countries to Fast-Track Vaccines for SARS-CoV-2 Variantshttps://modernod.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/A group of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland issued new rules Thursday aimed at speeding up the development of modified COVID-19 vaccines against emerging SAR-CoV-2 strains. The guidance, developed by the UK’s Medicines and Healthcare products
- FDA Outlines Faster Path for COVID-19 Vaccines That Tackle New Variantshttps://modernod.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/The FDA on Monday issued new guidance confirming that drugmakers will not have to perform large-scale trials for new COVID-19 vaccines or booster shots developed to combat new variants of SARS-CoV-2. “At this time, available information suggests that the FDA-authorized vaccines remain effec
- Single Dose of Pfizer, BioNTech’s COVID-19 Vaccine 85% Effective: Studyhttps://modernod.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/Study results published in The Lancet showed that a single dose of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 is 85% effective at preventing symptomatic disease 15 to 28 days after being administered. The data, which come from an analysis of healthcare workers in Israel, also
- GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primateshttps://modernod.com/news/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-none28091human-primates/2478834/GenSight Biologics announced that the journal Communications Biology has published results from the study of GS030-Drug Product (GS030-DP) in non-human primates (NHP). The paper,* published in the January issue under the title “Optogenetic therapy: high spatiotemporal resolution and
- Inflammasome Therapeutics Says Study Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-says-study-provides-human-data-confirming-potential-of-companys-proprietary-compounds-for-prevention-of-dry-amd/2478824/Inflammasome Therapeutics reported that data analyses published in the current issue of Proceedings of the National Academy of Sciences (PNAS) confirms that the company’s proprietary compounds hold significant promise in the prevention and treatment of dry age-related macular degeneration